Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador LE, Rodríguez-Otero P, Jiménez-Ubieto A, Rosiñol L, Oriol A, Ríos R, Sureda A, Blanchard MJ, Hernández MT, Cabañas Perianes V, Jarque I, Bargay J, Gironella M, De Arriba F, Palomera L, Gonzalez-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, Casado LF, González-Rodriguez AP, López-Anglada L, Puig N, Cedena MT, Paiva B, Mateos MV, San-Miguel J, Lahuerta JJ, Bladé J, Trocóniz IF. Tamariz-Amador LE, et al. Among authors: de arriba f. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):e844-e852. doi: 10.1016/j.clml.2022.04.024. Epub 2022 May 5. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35688793 Free article.
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J. de la Rubia J, et al. Among authors: de arriba f. Haematologica. 2006 May;91(5):621-7. Epub 2006 Apr 19. Haematologica. 2006. PMID: 16627253 Clinical Trial.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Mateos MV, et al. Among authors: de la rubia j, de arriba f. Blood. 2006 Oct 1;108(7):2165-72. doi: 10.1182/blood-2006-04-019778. Epub 2006 Jun 13. Blood. 2006. PMID: 16772605 Free article. Clinical Trial.
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ; Spanish Myeloma Group/PETHEMA. Carreras E, et al. Among authors: de arriba f. Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54. doi: 10.1016/j.bbmt.2007.08.002. Biol Blood Marrow Transplant. 2007. PMID: 18022574 Free article. Clinical Trial.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Mateos MV, et al. Among authors: de la rubia j, de arriba f. Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5. Haematologica. 2008. PMID: 18322252 Free article. Clinical Trial.
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF; PETHEMA Study Group; GEM Study Group. Mateo G, et al. Among authors: de la rubia j, de arriba f. J Clin Oncol. 2008 Jun 1;26(16):2737-44. doi: 10.1200/JCO.2007.15.4120. Epub 2008 Apr 28. J Clin Oncol. 2008. PMID: 18443352 Clinical Trial.
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.
Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, González JD, Díaz-Mediavilla J, Hernández B, García-Frade J, Carrera D, León A, Hernández M, Abellán PF, Bergua JM, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM). Rosiñol L, et al. Among authors: de la rubia j, de arriba f. Blood. 2008 Nov 1;112(9):3591-3. doi: 10.1182/blood-2008-02-141598. Epub 2008 Jul 8. Blood. 2008. PMID: 18612103 Free article. Clinical Trial.
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF. Lahuerta JJ, et al. Among authors: de la rubia j, de arriba f. J Clin Oncol. 2008 Dec 10;26(35):5775-82. doi: 10.1200/JCO.2008.17.9721. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001321
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, González Y, Bladé J, Lahuerta JJ, Orfao A, San-Miguel JF; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Paiva B, et al. Blood. 2009 Nov 12;114(20):4369-72. doi: 10.1182/blood-2009-05-221689. Epub 2009 Sep 15. Blood. 2009. PMID: 19755674 Free article.
100 results